Endpoints at #JPM25 - January 13-14, 2025 - San Francisco
In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.
Endpoints News – Biotech and pharma business news, with a focus …
Catalyst Pharmaceuticals' controversial $375,000 rare autoimmune disease drug now won't face generic competition from Teva until Feb. 25, 2035, thanks to a ...
Lilly’s oral SERD makes strides in breast cancer with Phase 3 data
Dec 11, 2024 · Data from a Phase 3 study in second-line breast cancer showed that Eli Lilly’s oral SERD reduced the risk of progression or death among patients with mutated estrogen receptor genes, but not in ...
Agenda: Endpoints at #JPM25 - events.endpts.com
How a new Washington affects biopharma: In conversation with Scott Gottlieb . Investor, policy expert and former FDA Commissioner Scott Gottlieb will share his insights on how the Trump administration’s new priorities will affect the biopharma industry, in what could be a turbulent time of policy and political changes.
Candel soars on prostate cancer data despite unclear prospects
Dec 11, 2024 · Candel Therapeutics’ viral immunotherapy candidate passed a late-stage test in certain patients with prostate cancer, sending its share price up around 60% even as the same treatment flunked a ...
NewAmsterdam hits primary endpoint in CETP inhibitor trial
Dec 10, 2024 · NewAmsterdam Pharma’s cardio drug succeeded in a third readout this year, showing that obicetrapib could lower a type of lipoprotein that carries cholesterol in the blood.
‘Unsupported’ drug price increases add to US costs, ICER claims
Dec 12, 2024 · ICER reports $800M+ annual US cost increase from 5 drugs (Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz) with 2023 price hikes deemed unsupported by new evidence.
FDA spells out expedited withdrawal process for accelerated …
Dec 5, 2024 · The FDA on Thursday released new details on how it plans to expedite the withdrawal of certain accelerated approvals when drugs fail to show clinical benefit in confirmatory trials, as recently ...
The Endpoints 11 winners: Big bets on AI, new frontiers in editing, …
Sep 27, 2024 · The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry
Lilly to study obesity drugs in addiction, and is considering …
Dec 11, 2024 · With supply shortages fading and new indications growing, the main question for obesity drugmakers entering the new year is what they’ll try and treat next …